$404 Million is the total value of BVF INC/IL's 32 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 18.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $47,657,000 | -20.6% | 2,640,251 | +15.9% | 11.79% | +15.3% |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $37,638,000 | -11.1% | 2,755,318 | +23.4% | 9.31% | +29.1% |
| CYTK | Buy | CYTOKINETICS INC | $30,602,000 | +0.2% | 4,340,729 | +48.6% | 7.57% | +45.5% |
| CTIC | Buy | CTI BIOPHARMA CORP | $23,805,000 | -55.8% | 44,796,940 | +2.3% | 5.89% | -35.8% |
| ARRY | Buy | ARRAY BIOPHARMA INC | $23,158,000 | -17.9% | 7,850,211 | +17.5% | 5.73% | +19.2% |
| Buy | EXELIXIS INCnote 4.250% 8/1 | $22,723,000 | +2.4% | 22,822,778 | +21.1% | 5.62% | +48.7% | |
| CCXI | Buy | CHEMOCENTRYX INC | $20,373,000 | -62.3% | 8,182,052 | +22.5% | 5.04% | -45.3% |
| VTAE | Buy | VITAE PHARMACEUTICALS INC | $13,850,000 | -62.9% | 2,089,014 | +1.3% | 3.43% | -46.1% |
| OMED | Buy | ONCOMED PHARMACEUTICALS INC | $13,541,000 | -39.4% | 1,339,336 | +35.1% | 3.35% | -12.0% |
| ARQL | Buy | ARQULE INC | $12,629,000 | -14.5% | 7,893,324 | +15.9% | 3.12% | +24.1% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $12,411,000 | +37.1% | 1,775,572 | +57.7% | 3.07% | +99.2% |
| QLTI | Buy | QLT INC | $11,346,000 | -20.5% | 5,701,609 | +6.3% | 2.81% | +15.5% |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $10,261,000 | – | 606,801 | +100.0% | 2.54% | – |
| CPXX | New | CELATOR PHARMACEUTICALS INC | $8,824,000 | – | 800,000 | +100.0% | 2.18% | – |
| NVLS | Buy | NIVALIS THERAPEUTICS INC | $6,450,000 | -30.3% | 1,546,743 | +29.4% | 1.60% | +1.3% |
| GTXI | Buy | GTX INC DEL | $5,756,000 | -26.3% | 11,512,000 | +3.1% | 1.42% | +6.9% |
| PTIE | Buy | PAIN THERAPEUTICS INC | $4,794,000 | +47.9% | 2,149,913 | +16.1% | 1.19% | +114.5% |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $2,599,000 | -39.4% | 4,813,294 | +0.8% | 0.64% | -12.0% |
| RXDX | New | IGNYTA INC | $339,000 | – | 50,000 | +100.0% | 0.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-10 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.